share_log

Takeda Pharmaceutical | 6-K: Takeda intends to rapidly initiate the first global Phase 3 trials of TAK-861, an oral orexin agonist, in narcolepsy type 1 in first half of fiscal year 2024

Takeda Pharmaceutical | 6-K: Takeda intends to rapidly initiate the first global Phase 3 trials of TAK-861, an oral orexin agonist, in narcolepsy type 1 in first half of fiscal year 2024

武田製藥 | 6-K:武田製藥計劃於在2024財年上半年迅速啓動口服奧曲肽激動劑TAK-861治療1型嗜睡症的首批全球3期試驗
美股sec公告 ·  02/09 06:09
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息